每经头条（nbdtoutiao）——展望"十五五" | 专访黄群慧：既要重视AI赋能千行百业，也要考量其对就业 的替代效应和带来的收入极化 （记者 曾健辉） 每经AI快讯，泰恩康（SZ 301263，收盘价：28.5元）发布公告称，2025年11月21日08:30-09:30，泰恩 康接受东方证券等投资者调研，公司董事、副总经理兼董事会秘书李挺先生参与接待，并回答了投资者 提出的问题。 2024年1至12月份，泰恩康的营业收入构成为：医药代理占比61.1%，医药制造占比37.28%，医药技术 服务占比1.51%，其他业务占比0.12%。 截至发稿，泰恩康市值为121亿元。 ...

Core Viewpoint - *ST Guohua announced the convening of its 2025 seventh temporary board meeting, discussing the proposal for the first temporary shareholders' meeting of 2025, indicating ongoing corporate governance activities [1] Financial Performance - For the first half of 2025, *ST Guohua's revenue composition was as follows: mobile network security accounted for 82.23%, medical technology services for 12.49%, other services for 3.65%, and emergency industry for 1.64% [1] - The company's market capitalization is currently 1.4 billion yuan [1]

Core Viewpoint - The company, 泰恩康, announced the convening of its fifth board meeting to review the 2025 semi-annual report and its summary, indicating ongoing corporate governance and financial transparency [1]. Financial Performance - For the year 2024, 泰恩康's revenue composition is as follows: pharmaceutical agency accounts for 61.1%, pharmaceutical manufacturing for 37.28%, pharmaceutical technology services for 1.51%, and other businesses for 0.12% [1]. - The current market capitalization of 泰恩康 is 15.4 billion yuan [1].

Core Viewpoint - 泰恩康 is set to hold an investor meeting on August 4, 2025, with participation from its chairman and general manager, Zheng Hanjie, to address investor inquiries [2]. Company Overview - For the year 2024, 泰恩康's revenue composition is as follows: - Pharmaceutical agency accounts for 61.1% - Pharmaceutical manufacturing accounts for 37.28% - Pharmaceutical technology services account for 1.51% - Other businesses account for 0.12% [2].